Improved Outcomes in HCV Patients Following Liver Transplantation During the Era of Direct-Acting Antiviral Agents
Clin Gastroenterol Hepatol
.
2018 Mar;16(3):452-453.
doi: 10.1016/j.cgh.2017.08.020.
Epub 2017 Aug 31.
Authors
George Cholankeril
1
,
Andrew A Li
1
,
Katherine L March
2
,
Eric R Yoo
3
,
Donghee Kim
1
,
Heather Snyder
2
,
Stevan A Gonzalez
4
,
Zobair M Younossi
5
,
Aijaz Ahmed
6
Affiliations
1
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California.
2
Division of Gastroenterology and Hepatology, University of Tennessee Health Science Center, Memphis, Tennessee.
3
Department of Medicine, University of Illinois College of Medicine, Chicago, Illinois.
4
Simmons Transplant Institute, Baylor All Saints Medical Center, Fort Worth, Texas.
5
Department of Medicine, Inova Fairfax Hospital, Falls Church, Virginia.
6
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California. Electronic address:
[email protected]
.
PMID:
28838786
DOI:
10.1016/j.cgh.2017.08.020
No abstract available
MeSH terms
Adult
Antiviral Agents / therapeutic use*
Female
Hepatitis C, Chronic / therapy*
Humans
Liver Transplantation*
Male
Middle Aged
Secondary Prevention / methods*
Treatment Outcome
Substances
Antiviral Agents